Global Enteric Softgel Capsules Market was valued at USD 2.4 Billion in 2022 and is projected to reach USD 3.1 Billion by 2030, growing at a CAGR of 4.2% from 2022 to 2030.

Enteric Softgel Capsules Market Overview:

Enteric softgel capsule made by enteric-coating method, which is a health product or medicine in oral dosage form. Going into softgel capsule coating involves the application of polymer coatings to softgel capsules to protect against various properties of the drug product or drug, such as pH, odor, and taste.

Enteric-coated softgel capsules are usually a combination of gelatin, glycerin or sorbitol, opacifiers, and water. However, manufacturers in the enteric-coated softgel market have been able to replace gelatin in softgel shells with other non-gelatin polymers, such as those manufactured using starch.

Enteric-coated softgel capsules market players provide uniformity of content, oral bioavailability, and liquid and semi-solid drug formulations by introducing high-quality enteric-coated softgel capsules. The growing popularity of softgel capsule drugs further encourages the manufacturers in the enteric coated softgel capsule market to invest in advanced manufacturing technologies to launch high quality enteric softgel capsules.

The global Enteric Softgel Capsules market is the professional and accurate study of various business perspectives such as major key players, key geographies, divers, restraints, opportunities, and challenges. This global research report has been aggregated on the basis of various market segments and sub-segments associated with the global market.

Industry News and Key Developments

• In February 2019, ACG expanded its footprint in Brazil with the launch of its new capsules manufacturing plant in Pouso Alegre-Minas Gerais
• In February 2018, CapsCanada invested US$ 28 Mn in new 100,000 square foot K-CAPS facility with additional 50% capsule production increase; nearly 3-times the amount CapsCanada invested in a 2014 HPMC capsule expansion, to meet rising global demand for K-CAPS.
• In July 2017, Lonza completed the acquisition of Capsugel S.A. Under the agreement, Lonza paid US$ 5.5 Bn in cash, including refinancing of existing Capsugel debt of approximately US$ 2 Bn for the acquisition of Capsugel, a world leader in advanced oral dosage delivery technologies with a leading position in hard capsules.

Top Key Players include in the Enteric Softgel Capsules Market are

• Aenova Group GmbH
• BASF SE
• Catalent Inc.
• Colorcon Inc.
• Fuji Capsule Co.Ltd.
• Lonza Group AG
• Now Health Group Inc.
• ProCaps Group
• Super Spectrim
• Thermo Fisher Scientific Inc.
• others

Key Vendors:

Aenova Group GmbH is a German company that manufactures a wide range of pharmaceutical capsules, including hard gelatin capsules, soft gelatin capsules, and HPMC capsules. Aenova has facilities in over 20 countries and is a leading supplier to pharmaceutical companies around the world.

BASF SE is a German multinational chemical company that also manufactures pharmaceutical capsules. BASF has a long history in the pharmaceutical industry and is a leading supplier of gelatin capsules. BASF also manufactures HPMC capsules and other pharmaceutical excipients.

Catalent Inc. is an American company that is a leading provider of services and products to the pharmaceutical, biotechnology, and consumer health industries. Catalent manufactures a wide range of pharmaceutical capsules, including hard gelatin capsules, soft gelatin capsules, and HPMC capsules. Catalent has facilities in over 30 countries and is a leading supplier to pharmaceutical companies around the world.

Colorcon Inc. is an American company that manufactures a wide range of pharmaceutical excipients, including pharmaceutical capsules. Colorcon has a long history in the pharmaceutical industry and is a leading supplier of gelatin capsules. Colorcon also manufactures HPMC capsules and other pharmaceutical excipients.

Fuji Capsule Co., Ltd. is a Japanese company that is a leading manufacturer of pharmaceutical capsules. Fuji Capsule has a long history in the pharmaceutical industry and is a leading supplier of gelatin capsules. Fuji Capsule also manufactures HPMC capsules and other pharmaceutical excipients.

The Enteric Softgel Capsules market research report is categorized based on type, applications and region.

On the Basis of Type:

• Gelatin Type
• Vegetable Type

Gelatin capsules are made from animal products, typically pork or beef. They are clear and colorless, and they dissolve easily in the stomach. Gelatin capsules are less expensive to produce than vegetable capsules, and they are more widely available. However, some people may avoid gelatin capsules because they are not vegetarian or vegan.

Vegetable capsules are made from plant-based materials, such as cellulose or hydroxypropyl methylcellulose (HPMC). They are typically brown or white, and they dissolve more slowly than gelatin capsules. Vegetable capsules are more expensive to produce than gelatin capsules, but they are a good option for people who are vegetarian or vegan.

On the Basis of Application:

• Antacid and Antiflatulent Preparations
• Antibiotic and Antibacterial Drugs

Antacids are used to neutralize stomach acid, which can help relieve heartburn, indigestion, and sour stomach. They work by binding to stomach acid and forming a chalky substance that is less acidic.
Antiflatulents are used to reduce gas in the stomach and intestines. They work by absorbing gas, breaking it down, or helping it pass through the digestive system more easily.
Antibiotics are used to kill or slow the growth of bacteria. They are used to treat a wide variety of bacterial infections, including strep throat, pneumonia, and urinary tract infections.
Antibacterial drugs are also used to kill or slow the growth of bacteria, but they are not as powerful as antibiotics. They are often used to treat mild bacterial infections or to prevent infections from spreading.

By Distribution Channel:

• Supermarkets and Hypermarkets
• Pharmacy and Drug Stores
• Online Stores

On the Basis of Region:

North America is the largest market for enteric softgel capsules, accounting for the largest share of the global market. This is due to the high demand for enteric softgel capsules in the pharmaceutical industry in the region. The United States is the largest market for enteric softgel capsules in North America.

Europe is the second largest market for enteric softgel capsules, accounting for a significant share of the global market. This is due to the increasing demand for enteric softgel capsules in the pharmaceutical and dietary supplement industries in the region. Germany, France, and the United Kingdom are the leading markets for enteric softgel capsules in Europe.

Asia Pacific is the fastest growing market for enteric softgel capsules, accounting for a significant share of the global market. This is due to the increasing demand for enteric softgel capsules in the pharmaceutical and dietary supplement industries in the region. China and India are the leading markets for enteric softgel capsules in Asia Pacific.

Latin America is a relatively small market for enteric softgel capsules, but it is expected to grow at a significant rate in the coming years. This is due to the increasing demand for enteric softgel capsules in the pharmaceutical and dietary supplement industries in the region. Brazil and Mexico are the leading markets for enteric softgel capsules in Latin America.

Middle East & Africa is a relatively small market for enteric softgel capsules, but it is expected to grow at a significant rate in the coming years. This is due to the increasing demand for enteric softgel capsules in the pharmaceutical and dietary supplement industries in the region. Saudi Arabia and South Africa are the leading markets for enteric softgel capsules in Middle East & Africa.

Further the regions are divided into countries as follows

• North America
• US
• Canada
• Mexico
• Rest of North America
• Europe
  • Denmark
  • Finland
  • Iceland
  • Sweden
  • Norway
  • Belgium
  • The Netherlands
  • Luxembourg
• Germany
• France
• Italy
• Spain
• UK
• Nordic Countries
• Benelux Union
• Rest of Europe
• Asia-Pacific
  • Indonesia
  • Thailand
  • Malaysia
  • Singapore
  • Rest of Southeast Asia
• Japan
• China
• India
• Australia
• South Korea
• Southeast Asia
• Rest of Asia-Pacific
• The Middle East & Africa
• Saudi Arabia
• UAE
• Egypt
• South Africa
• Rest of the Middle East & Africa
• Latin America
• Brazil
• Argentina
• Rest of Latin America

Significant Market Dynamics:

Market Dynamics

• Growing demand for enteric softgel capsules in the pharmaceutical industry: Enteric softgel capsules are increasingly being used to deliver drugs that are sensitive to stomach acid. This is because the enteric coating on enteric softgel capsules protects the drug from being broken down by stomach acid until it reaches the small intestine.
• Increasing demand for enteric softgel capsules in the dietary supplement industry: Enteric softgel capsules are increasingly being used to deliver dietary supplements that are sensitive to stomach acid. This is because the enteric coating on enteric softgel capsules protects the dietary supplement from being broken down by stomach acid until it reaches the small intestine.
• Growing awareness of the benefits of enteric softgel capsules: Consumers are becoming increasingly aware of the benefits of enteric softgel capsules, such as their ability to protect drugs and dietary supplements from stomach acid and their ability to improve the absorption of these products.
• Advancements in encapsulation technologies: There have been significant advancements in encapsulation technologies in recent years, which has led to the development of more advanced enteric softgel capsules. These new capsules have improved properties, such as increased stability, better taste, and more targeted delivery.

Restraints

• High manufacturing costs: The manufacturing of enteric softgel capsules is a complex process, which can lead to high manufacturing costs. This can be a barrier to entry for some companies, and it can also make it difficult for smaller companies to compete with larger companies.
• Regulatory requirements: The enteric softgel capsules market is subject to a number of regulatory requirements, which can add to the cost of doing business in this market. These requirements can also make it difficult for new products to be brought to market.

Drivers

• Increased focus on patient-centric drug delivery: There is a growing focus on patient-centric drug delivery, which is driving the development of more personalized enteric softgel capsules. These capsules can be tailored to the specific needs of individual patients, which can improve the efficacy and safety of drug delivery.
• Advances in targeted drug delivery: There have been significant advances in targeted drug delivery in recent years, which has led to the development of more advanced enteric softgel capsules. These capsules can be designed to release the drug in a specific location in the body, which can improve the efficacy of drug delivery.

Trends

• Growth of the dietary supplement market: The dietary supplement market is growing rapidly, which is creating new opportunities for enteric softgel capsules. Enteric softgel capsules are well-suited for delivering dietary supplements, as they can protect the supplements from stomach acid and improve their absorption.
• Development of new enteric coating materials: The development of new enteric coating materials could offer new opportunities for enteric softgel capsules. These new materials could offer improved properties, such as increased stability, better taste, and more targeted delivery.

Challenges

• Competition from other drug delivery systems: Enteric softgel capsules face competition from other drug delivery systems, such as tablets, capsules, and injectables. These other systems may offer some advantages over enteric softgel capsules, such as lower cost or faster onset of action.
• Patent expiry: The expiry of patents for some key enteric softgel capsules could lead to increased competition in the market. This could put pressure on prices and margins.

Opportunities

• Rise in the number of chronic diseases: The rise in the number of chronic diseases, such as diabetes and cancer, is creating new opportunities for enteric softgel capsules. These capsules can be used to deliver drugs that are used to treat these diseases.
• Increased demand for personalized medicine: The increasing demand for personalized medicine is creating new opportunities for enteric softgel capsules. These capsules can be tailored to the specific needs of individual patients, which can improve the efficacy and safety of drug delivery.

Scope of Reports:

Report Attribute	Details
Study Period	2017-2030
Base Year	2022
Estimated year	2023
Forecast period	2023-2030
Historic Period	2017-2022
Units	USD 3.1 Billion
Growth Rate	CAGR of 4.2% from 2022 to 2030
By Type	Gelatin Type Vegetable Type
By Application	Antacid and Antiflatulent Preparations Antibiotic and Antibacterial Drugs
By Companies	Aenova Group GmbH BASF SE Catalent Inc. Colorcon Inc. Fuji Capsule Co.Ltd. Lonza Group AG Now Health Group Inc. ProCaps Group Super Spectrim Thermo Fisher Scientific Inc. others
Regional Scope	North America Europe Asia-Pacific The Middle East & Africa Latin America
Reasons to Purchase this Report and Customization Scope	6-month post-sale analyst assistance. 10% Free Customization and 15 Company Profiles in addition to the ones specified

Conclusion:
                  In conclusion, the enteric softgel capsules market is poised for continued growth as pharmaceutical companies seek innovative drug delivery solutions and consumers demand more effective and patient-friendly medications. With their targeted release mechanism, improved bioavailability, and enhanced patient compliance, enteric softgel capsules offer numerous advantages and are likely to play a significant role in the future of oral dosage forms.